Informationen:
Fehler:
ID
31625
Beschreibung
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00895466
Link
https://clinicaltrials.gov/show/NCT00895466
Stichworte
Versionen (1)
- 14.09.18 14.09.18 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
14. September 2018
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Prostate Cancer NCT00895466
Eligibility Prostate Cancer NCT00895466
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Prostate Cancer NCT00895466
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Adenocarcinoma of prostate TNM clinical staging
Item
pathological confirmed prostatic adenocarcinoma, clinical stage (c) ct1-3, cn0-1/x, cm0
boolean
C0007112 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,2])
Testosterone measurement
Item
baseline testosterone levels of > 4 nmol/l
boolean
C0523912 (UMLS CUI [1])
Prostate specific antigen measurement
Item
baseline psa level of > 10 microg/l
boolean
C0201544 (UMLS CUI [1])
Eligibility Hormone Therapy
Item
eligible for hormone therapy
boolean
C1548635 (UMLS CUI [1,1])
C0279025 (UMLS CUI [1,2])
C0279025 (UMLS CUI [1,2])
Protocol Compliance
Item
willingness to comply with the protocol conditions and procedures
boolean
C0525058 (UMLS CUI [1])
Informed Consent
Item
willing and able to give informed consent
boolean
C0021430 (UMLS CUI [1])
Distant metastasis
Item
clinical evidence of distant metastases
boolean
C1269798 (UMLS CUI [1])
Prior Hormone Therapy Prostate carcinoma
Item
previous hormonal therapy administered specifically for prostatic carcinoma
boolean
C1514460 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,2])
Invasive cancer | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin
Item
development of another invasive neoplastic disease during the previous 5 years, or concomitant presence of another invasive neoplastic disease, except basal cell carcinoma or squamous cell carcinoma of the skin
boolean
C0677898 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
Primary immunodeficiency | Secondary immunodeficiency | Immunosuppression | Adrenal Cortex Hormones | Immunosuppressive Agents
Item
primary or secondary immunodeficiency, including immunosuppressive disease or use of corticosteroids or other immunosuppressive medications
boolean
C0398686 (UMLS CUI [1])
C0398795 (UMLS CUI [2])
C4048329 (UMLS CUI [3])
C0001617 (UMLS CUI [4])
C0021081 (UMLS CUI [5])
C0398795 (UMLS CUI [2])
C4048329 (UMLS CUI [3])
C0001617 (UMLS CUI [4])
C0021081 (UMLS CUI [5])
Immunologic Adjuvants | Testosterone Supplement
Item
concomitant administration - or administration during the 12 weeks preceding study inclusion - of immune enhancing medication or testosterone supplements
boolean
C0001551 (UMLS CUI [1])
C0039601 (UMLS CUI [2,1])
C2348609 (UMLS CUI [2,2])
C0039601 (UMLS CUI [2,1])
C2348609 (UMLS CUI [2,2])
Therapeutic radiology procedure Prostate carcinoma
Item
concomitant radiotherapy for prostate cancer
boolean
C1522449 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,2])
Bacterial prostatitis Causing Raised prostate specific antigen
Item
presence of bacterial prostatitis causing a psa increase during the 8 weeks preceding study inclusion
boolean
C0748023 (UMLS CUI [1,1])
C0678227 (UMLS CUI [1,2])
C0178415 (UMLS CUI [1,3])
C0678227 (UMLS CUI [1,2])
C0178415 (UMLS CUI [1,3])
Study Subject Participation Status | Investigational New Drugs
Item
simultaneous participation in another clinical trial or participation in a clinical trial involving investigational drugs within 3 months before enrollment into the present study
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0013230 (UMLS CUI [2])
Body mass index
Item
bmi > 30 kg/square meter
boolean
C1305855 (UMLS CUI [1])
Reaction Serious Vaccines | Angioedema | Anaphylaxis
Item
previous serious reaction to a vaccine such as angioedema or anaphylaxis
boolean
C0443286 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0042210 (UMLS CUI [1,3])
C0002994 (UMLS CUI [2])
C0002792 (UMLS CUI [3])
C0205404 (UMLS CUI [1,2])
C0042210 (UMLS CUI [1,3])
C0002994 (UMLS CUI [2])
C0002792 (UMLS CUI [3])